Infectious Diseases News and Research

RSS

Study reveals how two proteins enable drug-resistant MRSA bacterium to secrete toxins

Antimicrobial resistance represents one of the top 10 global public health threats according to the World Health Organization, and scientists have been scrambling to find new tools to cure the most deadly drug-resistant infections.

14 Feb 2023

Extracts from two common wild plants block SARS-CoV-2 from entering human cells

Two common wild plants contain extracts that inhibit the ability of the virus that causes COVID-19 to infect living cells, an Emory University study finds.

13 Feb 2023

Novel compound curtails influenza virus replication

Viruses use the molecular repertoire of the host cell to replicate. Researchers from the Cluster of Excellence ImmunoSensation2 at the University of Bonn, together with Japanese researchers, want to exploit this for the treatment of influenza.

10 Feb 2023

Protein that facilitates cancer-causing viruses dodge the immune system

Numerous cancers have been related to the viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV). For the first time, UNC School of Medicine researchers have shown that these viruses elude the innate immune response by using a human protein called barrier-to-autointegration factor 1, or BAF, which enables the viruses to propagate and cause disease.

7 Feb 2023

Gaining insights into human disease biology through CRISPR platforms

In this interview, we speak with Laralynne Przybyla about how she is utilizing CRISPR platforms to understand human disease biology in greater detail.

From Society for Laboratory Automation and Screening (SLAS) 7 Feb 2023

Study identifies genetic mutation in the SPTSSA gene as cause of Hereditary Spastic Paraplegia

A genetic mutation in the SPTSSA gene is identified as the cause of Hereditary Spastic Paraplegia, a rare disease that causes progressive weakness, stiffness and spasticity in the lower extremities, according to a study, "SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia," published in Brain on on Jan. 30.

1 Feb 2023

Novel chemical tool reveals how bacteria adapt to the host environment

A research team guided by Professor Xiang David Li of The University of Hong Kong’s (HKU) Department of Chemistry created a new chemical tool to unveil how bacteria adjust to the host environment and control host cells.

1 Feb 2023

UNC research describes another layer to the challenge of HIV latency

When people living with HIV take antiviral therapy (ART), their viral loads are driven so low that a standard blood test cannot detect the virus.

1 Feb 2023

Genomic study helps retrace origin and spread of Shigellosis outbreak in Seattle

A genomic study of a sustained, multidrug-resistant Shigellosis outbreak in Seattle enabled scientists to retrace its origin and spread.

1 Feb 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

New genetic condition that raises vulnerability to opportunistic infections

An international consortium co-led by Vanderbilt University Medical Center immunogeneticist Rubén Martínez-Barricarte, PhD, has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including life-threatening fungal pneumonia.

24 Jan 2023

Detecting the extent of natural selection over time

Institut Pasteur, Université Paris Cité, the CNRS, and the Collège de France researchers have employed paleogenomics to trace 10,000 years of human immune system evolution. They examined the genomes of over 2,800 individuals who lived in Europe over the past 10 millennia.

From Institut Pasteur 18 Jan 2023

A new-found possibility for viral and cancer drug therapies

Researchers have found that sugar-based molecules can be used to inhibit the activity of a cell receptor that plays a role in the emergence of a variety of viral infections and cancers.

13 Jan 2023

New DNA analysis leads to first accurate tuberculosis genome identification

A novel genome assembly tool that has been created by researchers could lead to the creation of fresh antibiotics for the bacterial infections that cause tuberculosis and other diseases.

From Rutgers University 20 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Small fluorescent protein helps researchers to capture deeper, more precise biomedical images

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.

7 Dec 2022

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022